The Sage Group

THE SAGE GROUP Reports That in 2008 Almost 1 million Interventional Procedures Were Performed to Treat Peripheral Artery Disease

ATLANTA, June 22, 2010 (BUSINESS WIRE)—According to THE SAGE GROUP, almost 70% of the procedures performed to treat Peripheral Artery Disease (PAD) were endovascular (angioplasty, atherectomy and primary stenting). Surgery and amputation each accounted for less than 20% of the 2008 PAD interventional market.

“Over the last eleven years, the PAD interventional market has undergone significant change. Reflecting an almost 5-fold increase in endovascular procedures the market has shifted away from surgery to less-invasive catheter-based procedures,” stated Mary L. Yost, President of THE SAGE GROUP.

“Even though the surgical market share has declined by more than 50%, over 165,000 surgical procedures are still performed,” she continued. “In the future, we expect that endovascular therapies will continue to take share from surgical procedures so that by 2020 the surgical share will decline to under 10%,” predicted Yost.

“Unfortunately, over the past decade the number of PAD-related primary amputationshas remained relatively unchanged at almost 150,000. Diagnosis and treatment at less severe stages of the disease could enable a significant percentage of these lost limbs to be salvaged,” Ms. Yost continued.

According to Yost, “PAD currently represents an $800 million market opportunity for endovascular devices. Market expansion reflects an increase in procedures performed as well as new higher-priced devices employed. This is especially true in the femoropopliteal and tibioperoneal areas.”

“We estimate that in 2008 over 406,000 ‘plain old balloon’ angioplasties and 106,000 primary stent procedures were performed. Atherectomy declined to less than 60,000 procedures,” Ms. Yost commented.

“Our research indicates that femoropopliteal (above knee) disease represents the largest single opportunity for new endovascular devices with procedures forecast to expand to almost 1.6 million by 2020,” explained Yost. “Although the tibioperoneal market is much smaller in terms of total procedures, below knee procedures are forecast to grow at an extremely rapid pace to exceed 400,000 by 2020.”

“The key question is what happens to stenting in the femoropopliteal and tibioperoneal regions,” Ms. Yost declared. “In order to address this question we developed two models based on a series of complex assumptions regarding the future of primary stenting (stent deployment without prior dilation with angioplasty),” she elaborated.

“While primary stenting represents the majority in the aortoiliac region, it is relatively uncommon in the femoropopliteal vessels, and almost nonexistent in the below knee area. We expect that primary stenting will remain the preferred procedure in the aortoiliac and continue to gain share over time. Technological innovation will determine whether direct stent deployment becomes feasible above and below the knees,” Ms. Yost predicted.

Peripheral Artery Disease Interventional Market Analysis Based on Treatment with Angioplasty or Atherectomy

Employing ICD-9 data, this report analyzes the historical, current and future PAD interventional market based on treatment with angioplasty or atherectomy devices. THE SAGE GROUP’S PAD Projections Model is employed to forecast endovascular and surgical procedures through 2020.

Angioplasty/atherectomy, primary stent and total endovascular procedures are analyzed by vascular territory in the aortoiliac, femoropopliteal, and tibioperoneal regions and projected through 2020. These projections are based on a proprietary model.

THE SAGE GROUP, a research and consulting company, specializes in atherosclerotic disease in the lower limbs, specifically PAD (Peripheral Artery Disease), CLI (Critical Limb Ischemia) and ALI (Acute Limb Ischemia). The most recent research focuses on PAD and diabetic foot ulcers (DFU).

For additional information visit